Icahn Enterprises' Carl Icahn says Apple CEO Tim Cook is headed in the right direction, and explains why he is not a "short-termist."
Icahn Enterprises' Carl Icahn says Bill Ackman is "right up there" in trying to change what's going on in American business.
Icahn Enterprises' Carl Icahn speaks to CNBC's Scott Wapner about the role and benefit of activism on company boards. He says a "board shouldn't be a country club."
In an op-ed published in Barron's, Carl Icahn said Warren Buffett was wrong to abstain in the vote over Coca-Cola's executive compensation plan. Carl Icahn speaks to CNBC's Scott Wapner about making CEOs accountable.
Apple is expanding to medical technology. The company is recruiting a team of medical executives and has offered hints of the iWatch and others.
Jeff Ubben of ValueAct believes that some of his fellow corporate agitators are doing undue harm to companies.
"I definitely believe we help a great deal," says activist investor Carl Icahn, No. 17 on the CNBC 25 list.
Are Bill Ackman and Carl Icahn laying down their weapons and calling an apparent end to their long-running feud? CNBC's Jeff Cox explains.
Bill Ackman and Carl Icahn, whose epic battle on CNBC stunned Wall Street, exchanged pleasantries last week and decided to forgive each other.
Transforms reputation as corporate raider into shareholder activist by launching proxy fights to hold feet of under-performing boards to the fire.
The "Squawk on the Street" news team discuss Apple's 7-for-1 stock split, 8% dividend boost and a $30 billion increase in its share buyback program. Cramer says this is all about Apple growing the company.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
CNBC's David Faber asks investor Carl Icahn if he succeeded in his eBay and Apple campaigns. Icahn also discuss his plans to seed other activist funds.
Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.
When asked how much he'd like to invest in seeding new activist funds, Icahn said investing $1 billion would be extremely immaterial to his firm.
CNBC's David Faber and Carl Icahn, chairman, Icahn Enterprises, discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman's recent efforts to partner with Valeant and acquire Allergan.
Virtually every Pershing Square Capital investment appears to have made money this year.
It's Talking Squawk, the official "Squawk Box" blog, this week with Bill Miller on bitcoin, a truce between eBay and Carl Icahn, and Sam Zell on taxes.
These are short-term, millionaire investors looking out for themselves, says Jacob Zamansky, Zamansky & Associates Partner, sharing his opinions on activist investors.
Carl Icahn and eBay struck a deal for Icahn to end his demand the company sell a minority stake in its PayPal unit to shareholders. CNBC's Scott Wapner provides insight into his interview with Icahn on "Fast Money Halftime Report."